Research programme: anti-GARP monoclonal antibodies - argenxAlternative Names: ARGX-115
Latest Information Update: 02 Mar 2017
At a glance
- Originator Catholic University of Louvain; Ludwig Institute for Cancer Research
- Developer argenx; Catholic University of Louvain
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer